Current commercial tests often fall below 50% specificity—about one false alarm for every two men flagged. A partnership with the Mayo Clinic has been formed to address this. No blood draws. No rectal

Over 20M PSA tests are run annually; most positives are false alarms, leading to 1M+ unnecessary, painful biopsies, while dangerous cancers can be missed.

A high PSA result often triggers months of anxiety, invasive procedures, and uncertainty.

The bladder cancer test (BCDx) shows 92% sensitivity and 97% specificity from a simple urine sample. Importantly, high-grade tumors that the current gold standard misses are detected. The Next Mountain:

Standard of care (cystoscopy): invasive, repeated every 3–6 months.

This effort began with bladder cancer because the current standard of care is brutal. About 800,000 people undergo surveillance with invasive cystoscopies that still miss ~20% of tumors. A multisite

Combining the three gives a fuller picture: DNA reveals which mutations are present RNA reveals what the cancer is doing Proteins reveal how the body is responding The Proof: Bladder Cancer

That technology reads DNA, RNA, and proteins simultaneously from a single sample. Proteins are detected at attomolar sensitivity (~1000x ELISA) and RNAs at PCR-level sensitivity, all without extraction

Many diagnostics fail because they search for a needle in a haystack, producing modest results with many false positives and negatives. Nanotechnology was developed that amplifies the signal, making it

This is a mid-decade update after five years of work. Meaningful progress has been achieved. The Engineering Unlock: Multiomics

Five years ago, a sibling trio of Purdue graduates from Indianapolis proposed a simple thesis: the science in detection and treatment isn’t the bottleneck—the engineering is. A company called EarlyIsGood

The result: many patients are overtreated while dangerous cancers are missed until it’s too late.

Clinicians often must make irreversible calls—biopsy or wait, treat or observe, remove an organ or monitor—based on tests that cannot capture the full biology of the body or the tumor.

Some of the toughest choices in cancer care are what to do and when: biopsy, resection, or passive monitoring.

Everything about cancer sucks

Q1 roadmap includes collaborative editing, a test case management module, background agents to further scrutinize requirements, and additional planned features

Next release will include: • Suggestion interface improvements to keep open suggestions persistent across sessions • Document versioning upgrades and version control for work orders

• Agent Framework UX overhaul: scrolling control during streaming, real-time visible thinking tokens, and one-click access to retrieved sources • Structured Q&A tool: agents ask via a form supporting

Another week, another Software Factory release

Every day feels very exciting